As soon as possible in IgE-cow’s milk allergy immunotherapy

Calvo, Javier Boné; Adell, Marcos Clavero; Abadía, I. Guallar; Aznar, Sara Laliena; Rodríguez, María Luisa Sancho; Monzón, Ángela Claver; Mazas, Yolanda Aliaga

doi:10.1007/s00431-020-03731-3

Cited by 23 publications

(37 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study confirmed the long‐term safety of E‐OIT for CMA of other reports 1,2,4 . Besides, it challenged the paradigm of the need for CM withdrawal to discern between desensitization and tolerance.…”

Section: Discussionsupporting

confidence: 78%

“…This study confirmed the long‐term safety of E‐OIT for CMA of other reports. 1 , 2 , 4 Besides, it challenged the paradigm of the need for CM withdrawal to discern between desensitization and tolerance. In real life, this approach can be complicated, time‐consuming, and anxiety‐provoking for parents.…”

Section: Discussionmentioning

confidence: 99%

“…Since we had excluded infants reactive to a very small amount of CM (1 ml), we could not extend our results to this population, theoretically at higher risk of severe anaphylaxis during OIT. Nevertheless, in Bonè Calvo et al 4 's study on a larger population of infants with CMA, in which no one had been in advance excluded from OIT, no significant adverse reactions occurred, and the protocol was successfully concluded by 98% of participants. 4 …”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have described populations of infants diagnosed with IgE‐mediated cow's milk allergy (CMA) undergoing early introduction oral immunotherapy (E‐OIT). The vast majority of these patients successfully introduced cow's milk (CM) along with dairy products in their diet, consuming them regularly over an average time of about 6 months and with no significant adverse effects 1–4 …”

Section: Introductionmentioning

confidence: 99%

“…The vast majority of these patients successfully introduced cow's milk (CM) along with dairy products in their diet, consuming them regularly over an average time of about 6 months and with no significant adverse effects. 1 , 2 , 3 , 4 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Early introduction oral immunotherapy for IgE‐mediated cow's milk allergy: A follow‐up study confirms this approach as safe and appealing to parents

Badina

Levantino

Carrato

et al. 2021

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction Early introduction oral immunotherapy (E‐OIT) in the first year of life can be a safe treatment for infants with cow's milk allergy (CMA). Once the protocol is completed, doubts remain whether children achieve tolerance or remain desensitized. According to current guidelines, this is determined by an avoidance period followed by a re‐exposure to the food allergen during an in‐hospital oral food challenge (OFC). In real life, this approach can be complicated, time‐consuming, and anxiety‐provoking for parents. We assessed the long‐term safety of E‐OIT for CMA in a cohort of children who switched to an unrestricted diet without testing the achievement of tolerance at the end of the OIT protocol. Materials and Methods We performed a descriptive analysis of the clinical follow‐up of a cohort of children diagnosed with IgE‐mediated CMA and undergoing E‐OIT protocol in their first year of life. In a previous publication, the same cohort of patients had been studied to assess the feasibility of E‐OIT for CMA. In the present study, we reported the results of a telephone survey, carried out through a questionnaire to their families enquiring about milk consumption and other ongoing atopic conditions of children. Results After an average of 4 years from the start of E‐OIT, 62/73 patients (85% of the historical cohort) participated in the survey. Among them, all 56 patients who had previously successfully completed the protocol reported an unrestricted cow's milk intake. Ninety–three percent of these children did not experience any further allergic reactions, while the remaining 7% described only mild and transitory reactions until the 6‐month period after the end of the protocol. Conclusions This study confirmed the long‐term safety of E‐OIT for CMA and challenged the paradigm of the need for allergen food withdrawal to discern between desensitization and tolerance. It could be a starting point for planning future trials on this issue.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Early introduction oral immunotherapy for IgE‐mediated cow's milk allergy: A follow‐up study confirms this approach as safe and appealing to parents

Badina

Levantino

Carrato

et al. 2021

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

Oral immunotherapy for Immunoglobulin E‐mediated cow's milk allergy in children: A systematic review and meta analysis

Tang

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Backgound: Cow's milk allergy (CMA) is the most common allergy in infants that decreases the quality of life of patients and their families. Standard treatment for CMA is the strict avoidance of milk; new treatment strategies such as oral immunotherapy (OIT) have been sought for patients with CMA.We aimed to assess the clinical efficacy and safety of OIT in the treatment of children with immunoglobulin E-mediated CMA (IMCMA). Methods:We searched all randomized controlled trials in which OIT is used to treat children with IMCMA from five international electronic databases. We estimated a pooled risk ratio (RR) for each outcome using a Mantel-Haenzel fixed-effects model if statistical heterogeneity was low. Results: Eleven studies were chosen for meta-analysis, including a total of 469 children (242 OITs, 227 controls). One hundred and seventy-six patients (72.7%) in the OIT were desensitized compared with 49 patients (21.6%) in the control group (RR: 7.35, 95% confidence interval (CI): 2.82-19.13, p < .0001).The desensitization effect of OIT was particularly significant in children over 3 years old (RR: 18.05, 95% CI: 6.48-50.26, p < .00001). Although adverse effects were common, they usually involved mild reactions, but epinephrine use was more common in the OIT group (RR: 7.69, 95% CI: 2.16-27.33, p < .002). Conclusion:OIT can lead to desensitization in the majority of individuals with IMCMA, especially in patients over 3 years old. A major problem of OIT is the frequency of adverse events, although most are mild. OIT may be an alternative treatment in the future.

show abstract

“There's a chance we can overcome”: Parental perceptions on modified desensitization protocol for newly diagnosed toddlers

Colli¹,

Shand²,

McCusker³

et al. 2023

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

As soon as possible in IgE-cow’s milk allergy immunotherapy

Cited by 23 publications

References 11 publications

Early introduction oral immunotherapy for IgE‐mediated cow's milk allergy: A follow‐up study confirms this approach as safe and appealing to parents

Early introduction oral immunotherapy for IgE‐mediated cow's milk allergy: A follow‐up study confirms this approach as safe and appealing to parents

Oral immunotherapy for Immunoglobulin E‐mediated cow's milk allergy in children: A systematic review and meta analysis

“There's a chance we can overcome”: Parental perceptions on modified desensitization protocol for newly diagnosed toddlers

Contact Info

Product

Resources

About